Wave Life Sciences Files 8-K
Ticker: WVE · Form: 8-K · Filed: Oct 1, 2024 · CIK: 1631574
| Field | Detail |
|---|---|
| Company | Wave Life Sciences Ltd. (WVE) |
| Form Type | 8-K |
| Filed Date | Oct 1, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-k
TL;DR
Wave Life Sciences filed a routine 8-K, no new info.
AI Summary
Wave Life Sciences Ltd. filed an 8-K on October 1, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This filing indicates Wave Life Sciences is meeting its regulatory reporting obligations, but provides no new material information for investors at this time.
Risk Assessment
Risk Level: low — The filing is a standard regulatory report and does not disclose any new material risks or events.
Key Players & Entities
- Wave Life Sciences Ltd. (company) — Registrant
- October 1, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is for a Regulation FD Disclosure and to report Financial Statements and Exhibits.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is October 1, 2024.
What is the company's legal name and jurisdiction of incorporation?
The company's legal name is Wave Life Sciences Ltd., and it is incorporated in Singapore.
What is the company's IRS Employer Identification No.?
The company's IRS Employer Identification No. is 98-1356880.
What are the business address and phone number listed?
The business address is 7 Straits View #12-00, Marina One East Tower, Singapore, and the business phone number is 617-949-2900.
Filing Stats: 547 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-10-01 07:35:05
Key Financial Figures
- $0 — e of each exchange on which registered $0 Par Value Ordinary Shares WVE The N
Filing Documents
- d869189d8k.htm (8-K) — 26KB
- d869189dex991.htm (EX-99.1) — 42KB
- g869189ex99_1p10g1.jpg (GRAPHIC) — 238KB
- g869189ex99_1p11g1.jpg (GRAPHIC) — 190KB
- g869189ex99_1p12g1.jpg (GRAPHIC) — 205KB
- g869189ex99_1p13g1.jpg (GRAPHIC) — 174KB
- g869189ex99_1p14g1.jpg (GRAPHIC) — 220KB
- g869189ex99_1p15g1.jpg (GRAPHIC) — 250KB
- g869189ex99_1p16g1.jpg (GRAPHIC) — 157KB
- g869189ex99_1p17g1.jpg (GRAPHIC) — 264KB
- g869189ex99_1p18g1.jpg (GRAPHIC) — 326KB
- g869189ex99_1p19g1.jpg (GRAPHIC) — 282KB
- g869189ex99_1p1g1.jpg (GRAPHIC) — 235KB
- g869189ex99_1p20g1.jpg (GRAPHIC) — 136KB
- g869189ex99_1p21g1.jpg (GRAPHIC) — 322KB
- g869189ex99_1p22g1.jpg (GRAPHIC) — 205KB
- g869189ex99_1p23g1.jpg (GRAPHIC) — 295KB
- g869189ex99_1p24g1.jpg (GRAPHIC) — 139KB
- g869189ex99_1p25g1.jpg (GRAPHIC) — 135KB
- g869189ex99_1p26g1.jpg (GRAPHIC) — 263KB
- g869189ex99_1p27g1.jpg (GRAPHIC) — 233KB
- g869189ex99_1p28g1.jpg (GRAPHIC) — 174KB
- g869189ex99_1p29g1.jpg (GRAPHIC) — 166KB
- g869189ex99_1p2g1.jpg (GRAPHIC) — 363KB
- g869189ex99_1p30g1.jpg (GRAPHIC) — 142KB
- g869189ex99_1p31g1.jpg (GRAPHIC) — 312KB
- g869189ex99_1p32g1.jpg (GRAPHIC) — 287KB
- g869189ex99_1p33g1.jpg (GRAPHIC) — 228KB
- g869189ex99_1p34g1.jpg (GRAPHIC) — 201KB
- g869189ex99_1p35g1.jpg (GRAPHIC) — 171KB
- g869189ex99_1p36g1.jpg (GRAPHIC) — 149KB
- g869189ex99_1p37g1.jpg (GRAPHIC) — 260KB
- g869189ex99_1p38g1.jpg (GRAPHIC) — 175KB
- g869189ex99_1p3g1.jpg (GRAPHIC) — 277KB
- g869189ex99_1p4g1.jpg (GRAPHIC) — 238KB
- g869189ex99_1p5g1.jpg (GRAPHIC) — 319KB
- g869189ex99_1p6g1.jpg (GRAPHIC) — 276KB
- g869189ex99_1p7g1.jpg (GRAPHIC) — 207KB
- g869189ex99_1p8g1.jpg (GRAPHIC) — 158KB
- g869189ex99_1p9g1.jpg (GRAPHIC) — 286KB
- 0001193125-24-229513.txt ( ) — 12135KB
- wve-20241001.xsd (EX-101.SCH) — 3KB
- wve-20241001_lab.xml (EX-101.LAB) — 18KB
- wve-20241001_pre.xml (EX-101.PRE) — 11KB
- d869189d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. The following exhibit relating to Item 7.01 is furnished and not filed: Exhibit No. Description 99.1 Corporate Presentation of Wave Life Sciences Ltd. dated October 1, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. WAVE LIFE SCIENCES LTD. By: /s/ Kyle Moran Kyle Moran Chief Financial Officer Date: October 1, 2024